KCAT	Staphylococcus aureus	0.002	2-aminobenzoyl-Ile-Ala-Ala-Gly-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain C
KCAT	Staphylococcus aureus	0.0112	2-aminobenzoyl-Phe-Gly-Ala-Lys-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain A
KCAT	Staphylococcus aureus	0.012	2-aminobenzoyl-Ile-Ala-Lys-Asp-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain A
KCAT	Staphylococcus aureus	0.023	2-aminobenzoyl-Phe-Gly-Ala-Lys-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain C
KCAT	Staphylococcus aureus	0.032	2-aminobenzoyl-Ile-Ala-Lys-Asp-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain A
KCAT	Staphylococcus aureus	0.056	2-aminobenzoyl-Ile-Ala-Ala-Gly-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain A
KCAT	Staphylococcus aureus	0.089	2-aminobenzoyl-Ile-Ala-Lys-Asp-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain C
KCAT	Staphylococcus aureus	0.16	N-benzyloxycarbonyl-Phe-Leu-Glu-NH-p-nitroanilide	*pH 8.0-8.8
KCAT	Staphylococcus aureus	0.2	N-Suc-Gly-Phe-Gly-p-nitroanilide	*used for inhibition studies of staphopain identified from a novel staphylococcal thiol protease operon stpAB2CH-91
KCAT	Staphylococcus aureus	0.716	2-aminobenzoyl-Phe-Gly-Ala-Lys-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain A
KCAT	Staphylococcus aureus	0.886	2-aminobenzoyl-Ile-Ala-Ala-Gly-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&deg;C, staphopain A
KM	Staphylococcus aureus	0.0056	2-aminobenzoyl-Phe-Gly-Ala-Lys-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain A
KM	Staphylococcus aureus	0.154	2-aminobenzoyl-Phe-Gly-Ala-Lys-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain A
KM	Staphylococcus aureus	0.385	2-aminobenzoyl-Phe-Gly-Ala-Lys-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain C
KM	Staphylococcus aureus	0.0076	2-aminobenzoyl-Ile-Ala-Ala-Gly-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain A
KM	Staphylococcus aureus	0.1639	2-aminobenzoyl-Ile-Ala-Ala-Gly-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain A
KM	Staphylococcus aureus	0.271	2-aminobenzoyl-Ile-Ala-Ala-Gly-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain C
KM	Staphylococcus aureus	0.014	2-aminobenzoyl-Ile-Ala-Lys-Asp-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain C
KM	Staphylococcus aureus	0.5871	2-aminobenzoyl-Ile-Ala-Lys-Asp-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain A
KM	Staphylococcus aureus	0.612	2-aminobenzoyl-Ile-Ala-Lys-Asp-5-amino-2-nitrobenzoylamide	*pH 7.6, 37&Acirc;&deg;C, staphopain A
KM	Staphylococcus aureus	0.5	N-benzyloxycarbonyl-Phe-Leu-Glu-NH-p-nitroanilide	*pH 8.0-8.8
KM	Staphylococcus aureus	3.3	N-Suc-Gly-Phe-Gly-p-nitroanilide	*used as substrate for staphopain inhibition studies
KM	Staphylococcus aureus	0.032	cystatin D	*Ala10 bond hydrolyzed by staphopain A, truncation of cystatin D shown to cause alleviated inhibition of endogenous target enzymes investigated, disturbance of the host protease-inhibitor balance
KM	Staphylococcus aureus	0.033	cystatin C	*Gly11 bond hydrolyzed by staphopain A, N-terminal truncation shown to impair inhibition of additional targets, disturbance of the host protease-inhibitor balance
MW	Staphylococcus aureus	13000	*	*gel filtration
MW	Staphylococcus epidermidis	19832	*	*x * 19832, DNA sequence determination
MW	Staphylococcus aureus	21000	*	*x * 21000, ScpA, SDS-PAGE
MW	Staphylococcus aureus	22000	*	*x * 22000, SspB, SDS-PAGE
SA	Staphylococcus epidermidis	-999	*	*purified enzyme, spectrophotometrical assay
SA	Staphylococcus aureus	-999	*	*cloning and characterization of staphopain A2 and its inhibitor from a novel staphylococcal thiol protease operon (stpAB2CH-91), staphopain/staphostatin interaction and evolution of encoding operons analyzed, evidence of ancestral allelic duplication and parallel evolution of the protease/inhibitor pairs suggested
SA	Staphylococcus epidermidis	-999	*	*staphopain A of Staphylococcus epidermidis used for assessment of staphopain-staphostatin interactions, kinetics shown
SA	Staphylococcus warneri	-999	*	*ability of staphostatins to form a complex with the active site mutant C21A of Staphylococcus warneri staphopain determined by size exclusion chromatography
SA	Staphylococcus aureus	-999	*	*cystatin C assay to analyze the disturbance of the host protease-inhibitor balance by bacterial staphopains described, enzyme kinetic parameters shown; MALDI-TOF based time-course experiments of cleavage of cystatin C and D by staphopain A indicated, cystatin C assay to analyze the disturbance of the host protease-inhibitor balance by staphopain A described, enzyme kinetic parameters shown
SA	Staphylococcus aureus	-999	*	*proteolytic cleavage of the C-terminus of chemerin, the tazarotene-induced gene 2 protein TIG2, by staphopain B determined by SDS-PAGE, HPLC-analysis and MALDI-TOF, cell-activating potential of chemerin cleavage products determined, clinical isolates of Staphylococcus aureus shown to activate chemerin, activation determined in the presence of plasma inhibitors, no activation of chemerin by staphopain B mutants observed
SA	Staphylococcus aureus	-999	*	*peripheral blood neutrophils and monocytes exposed to SspB are extensively phagocytosed by resting human monocyte-derived macrophages in a time- and concentration-dependent manner. SspB-treated neutrophils engulfed in phagosomesstill preserve mitochondrial potential. SspB blocks phagocytosis of opsonised Staphylococcus aureus by neutrophils and monocytes. SspB blocks the chemotactic activity of neutrophils. SspB decreases surface expression of the major repulsion signal CD31 on neutrophils both in the absence and presence of human serum.
